Clinical and Translational Oncology

, Volume 16, Issue 3, pp 285–292 | Cite as

Combined preoperative CEA and CD44v6 improves prognostic value in patients with stage I and stage II colorectal cancer

  • L. Chen
  • B. Jiang
  • Z. Wang
  • M. Liu
  • H. Yang
  • J. Xing
  • C. Zhang
  • Z. Yao
  • N. Zhang
  • M. Cui
  • X. SuEmail author
Research Article



Combination of biomarkers may improve diagnosis and have better prognostic value than single markers. The purpose of this study was to investigate whether combined CEA and CD44v6 improves prognostic value in stage I and stage II (stage I/II) colorectal cancer (CRC).


Preoperative serum CEA level and the expression of CD44v6 in CRC tissues were examined by electrochemiluminescence immunoassay and immunohistochemistry, respectively. The association of CEA and CD44v6 with clinicopathological features and their possible prognostic values was analyzed.


The preoperative elevated serum CEA level and positive CD44v6 expression were detected in 30.1 % (52/173) serum samples and 60.5 % (101/167) CRC tissues, respectively. Patients with an elevated-CEA level or a CD44v6-negative tumor had a worse disease-specific survival (DSS) than those with a normal-CEA level or CD44v6-positive tumor (P = 0.024, P = 0.012, respectively). Moreover, CD44v6 expression could be used in discriminating patients from good to poor prognosis in normal-CEA subgroup (P = 0.043), but not in elevated-CEA subgroup (P = 0.563). Multivariate analysis revealed that combined CEA and CD44v6 was an independent prognostic factor for patients with stage I/II CRC (P = 0.023). However, serum CEA level only retained a borderline significance for correlation with a worse DSS (P = 0.059), and CD44v6 expression alone was not an independent prognostic factor for DSS in multivariate analysis (P = 0.123).


These results suggested that combined CEA/CD44v6 had better prognostic value than CEA or CD44v6 alone for patients with stage I/II CRC.


CEA CD44v6 Colorectal cancer Prognosis 



We thank Dr. Li Sun and Yiqiang Liu for histopathological diagnosis. We thank Dr. Jiabo Di for critical reading of the manuscript. This study was supported by the grants from the National Natural Science Foundation of China (No. 81272766 and No. 81071658), Capital Medical Development and Research Foundation (No. 2009-2093), Clinical Characteristics and Application Research of Capital (Beijing Municipal Science & Technology Commission No. Z121107001012130), Beijing Natural Science Foundation (No. 7132054), New Star of Science and Technology Program of Beijing (Beijing Municipal Science & Technology Commission No. 2011060).

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Zhao P, Dai M, Chen W, Li N. Cancer trends in China. Jpn J Clin Oncol. 2010;40:281–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36.PubMedCrossRefGoogle Scholar
  4. 4.
    Carlson MR, Previstage GCC. Colorectal cancer staging test: a new molecular test to identify lymph node metastases and provide more accurate information about the stage of patients with colorectal cancer. Mol Diagn Ther. 2009;13:11–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Tsikitis VL, Malireddy K, Green EA, Christensen B, Whelan R, Hyder J, et al. Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. J Clin Oncol. 2009;27:3671–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Shibayama M, Maak M, Nitsche U, Gotoh K, Rosenberg R, Janssen KP. Prediction of metastasis and recurrence in colorectal cancer based on gene expression analysis: ready for the clinic? Cancers. 2011;3:2858–69.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Yu X, McBean AM. Screening mammography use and chemotherapy among female stage II colon cancer patients: a retrospective cohort study. BMC Health Serv Res. 2010;10:98.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Bacolod MD, Barany F. Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition. Ann Surg Oncol. 2011;18:3694–700.PubMedCrossRefGoogle Scholar
  9. 9.
    Newton KF, Newman W, Hill J. Review of biomarkers in colorectal cancer. Colorectal Dis. 2012;14:3–17.PubMedCrossRefGoogle Scholar
  10. 10.
    Bohanes P, LaBonte MJ, Winder T, Lenz HJ. Predictive molecular classifiers in colorectal cancer. Semin Oncol. 2011;38:576–87.PubMedCrossRefGoogle Scholar
  11. 11.
    López-Gómez M, Casado E, Cejas P, Feliu J. Prognostic and predictive factors in colorectal cancer: The importance of reliable markers for effective selection of therapy. In: Esther Uña Cidón editor. The challenge of colorectal cancer: a review book. India: Research Signpost Press; 2011. p. 285–308.Google Scholar
  12. 12.
    Zlobec I, Baker K, Terracciano L, Peter S, Degen L, Beglinger C, et al. Two-marker protein profile predicts poor prognosis in patients with early rectal cancer. Br J Cancer. 2008;99:1712–7.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Liu C, Qu L, Dong B, Xing X, Ren T, Zeng Y, et al. Combined phenotype of 4 markers improves prognostic value of patients with colon cancer. Am J Med Sci. 2012;343:295–302.PubMedCrossRefGoogle Scholar
  14. 14.
    Peng Y, Wang L, Gu J. Elevated preoperative carcinoembryonic antigen (CEA) and Ki67 is predictor of decreased survival in IIA stage colon cancer. World J Surg. 2013;37:208–13.PubMedCrossRefGoogle Scholar
  15. 15.
    Li M, Li JY, Zhao AL, He JS, Zhou LX, Li YA, et al. Comparison of carcinoembryonic antigen prognostic value in serum and tumour tissue of patients with colorectal cancer. Colorectal Dis. 2009;11:276–81.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Chen L, Jiang B, Wang Z, Liu M, Ma Y, Yang H, et al. Expression and prognostic significance of GATA-binding protein 2 in colorectal cancer. Med Oncol. 2013;. doi: 10.1007/s12032-013-0498-7.Google Scholar
  17. 17.
    Peng J, Lu JJ, Zhu J, Xu Y, Lu H, Lian P, et al. Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer. Cancer J. 2008;14:54–61.PubMedCrossRefGoogle Scholar
  18. 18.
    Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med. 1965;121:439–62.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Sun LC, Chu KS, Cheng SC, Lu CY, Kuo CH, Hsieh JS, et al. Preoperative serum carcinoembryonic antigen, albumin and age are supplementary to UICC staging systems in predicting survival for colorectal cancer patients undergoing surgical treatment. BMC Cancer. 2009;9:288.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Huh JW, Oh BR, Kim HR, Kim YJ. Preoperative carcinoembryonic antigen level as an independent prognostic factor in potentially curative colon cancer. J Surg Oncol. 2010;101:396–400.PubMedGoogle Scholar
  21. 21.
    Tarantino I, Warschkow R, Worni M, Merati-Kashani K, Köberle D, Schmied BM, et al. Elevated preoperative CEA is associated with worse survival in stage I-III rectal cancer patients. Br J Cancer. 2012;107:266–74.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Fakih MG, Padmanabhan A. CEA monitoring in colorectal cancer. What you should know. Oncology (Williston Park). 2006;20:579–87.Google Scholar
  23. 23.
    Wanebo HJ, Rao B, Pinsky CM, Hoffman RG, Stearns M, Schwartz MK, et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med. 1978;299:448–51.PubMedCrossRefGoogle Scholar
  24. 24.
    Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R. Multivariate analysis of the prognostic value of CEA and CA 19–9 serum levels in colorectal cancer. Anticancer Res. 2000;20:5195–8.PubMedGoogle Scholar
  25. 25.
    Kirat HT, Ozturk E, Lavery IC, Kiran RP. The predictive value of preoperative carcinoembryonic antigen level in the prognosis of colon cancer. Am J Surg. 2012;204:447–52.PubMedCrossRefGoogle Scholar
  26. 26.
    Su BB, Shi H, Wan J. Role of serum carcinoembryonic antigen in the detection of colorectal cancer before and after surgical resection. World J Gastroenterol. 2012;18:2121–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Jung T, Gross W, Zöller M. CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance. J Biol Chem. 2011;286:15862–74.PubMedCrossRefGoogle Scholar
  28. 28.
    Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, Ponta H, et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res. 1993;53:4754–6.PubMedGoogle Scholar
  29. 29.
    Saito S, Okabe H, Watanabe M, Ishimoto T, Iwatsuki M, Baba Y, et al. CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer. Oncol Rep. 2013;. doi: 10.3892/or.2013.2273.Google Scholar
  30. 30.
    Zlobec I, Günthert U, Tornillo L, Iezzi G, Baumhoer D, Terracciano L, et al. Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer. Histopathology. 2009;55:564–75.PubMedCrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2013

Authors and Affiliations

  • L. Chen
    • 1
  • B. Jiang
    • 1
  • Z. Wang
    • 1
  • M. Liu
    • 1
  • H. Yang
    • 1
  • J. Xing
    • 1
  • C. Zhang
    • 1
  • Z. Yao
    • 1
  • N. Zhang
    • 1
  • M. Cui
    • 1
  • X. Su
    • 1
    Email author
  1. 1.Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Minimally Invasive Gastrointestinal SurgeryPeking University Cancer Hospital & InstituteBeijingChina

Personalised recommendations